T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms.
CD8
Castleman disease
FOXP3
HHV8 + MCD
T-cell
T-reg
UCD
iMCD
immunophenotyping
lymphoproliferative disorder
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
25 Apr 2023
25 Apr 2023
Historique:
received:
27
01
2023
revised:
14
04
2023
accepted:
19
04
2023
medline:
15
5
2023
pubmed:
13
5
2023
entrez:
13
5
2023
Statut:
epublish
Résumé
Castleman disease (CD) is a rare lymphoproliferative disorder that includes various clinico-pathological subtypes. According to clinical course, CD is divided into unicentric CD (UCD) and multicentric CD (MCD). MCD is further distinguished based on the etiological driver in herpes virus-8-related MCD (that can occur in the setting of HIV); in MCD associated with POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes); and idiopathic MCD (iMCD). The latter can also be divided in iMCD-TAFRO (thrombocytopenia, anasarca, fever, myelofibrosis, organomegaly) and iMCD not otherwise specified. To date, CD pathogenesis is still uncertain, but CD may represent the histological and clinical result of heterogeneous pathomechanisms. Transcriptome investigations in CD lymph nodes have documented the expression and up-regulation of different cytokines; furthermore, few recent studies have shown alterations of different T-cell subsets in CD patients, suggesting a possible role of the nodal microenvironment in CD development. On this basis, our study aimed to investigate the distribution of T-cell subsets in the clinico-pathological spectrum of CD. We evaluated the CD4/CD8 ratio and the number of T-regulatory (T-reg) FOXP3+ cells in 28 CD cases. In total, 32% of cases showed a decreased CD4/CD8 ratio due to increased CD8+ T-cells, including both UCD, iMCD, and HHV8+ MCD cases. The T-reg subset analysis revealed a statistically significant (
Identifiants
pubmed: 37175521
pii: ijms24097813
doi: 10.3390/ijms24097813
pmc: PMC10178230
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Forkhead Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Progetto di ricerca corrente IRCCS San Matteo Hospital Foundation
ID : not available
Références
Leukemia. 2022 Jul;36(7):1720-1748
pubmed: 35732829
Blood. 2000 Feb 15;95(4):1406-12
pubmed: 10666218
Pathol Int. 2016 Sep;66(9):535-9
pubmed: 27593552
Immunol Rev. 2006 Aug;212:8-27
pubmed: 16903903
Hematol Oncol Clin North Am. 2018 Feb;32(1):37-52
pubmed: 29157618
Cancer. 1972 Mar;29(3):670-83
pubmed: 4551306
J Clin Exp Hematop. 2022;62(2):79-84
pubmed: 35768240
Oncol Res Treat. 2022;45(11):693-704
pubmed: 36219975
Lung Cancer. 2018 Mar;117:73-79
pubmed: 29409671
J Clin Invest. 2019 Aug 13;129(10):4451-4463
pubmed: 31408438
Haematologica. 2023 Jan 01;108(1):207-218
pubmed: 35484648
Am J Hematol. 2018 Jul;93(7):902-912
pubmed: 29675946
Blood Adv. 2020 Dec 8;4(23):6039-6050
pubmed: 33284946
Pathol Int. 2020 Jul;70(7):391-402
pubmed: 32314497
Semin Immunol. 2014 Feb;26(1):38-47
pubmed: 24602448
Cell Mol Immunol. 2015 Sep;12(5):558-65
pubmed: 25683611
Blood. 2017 Mar 23;129(12):1646-1657
pubmed: 28087540
Front Immunol. 2022 Aug 01;13:943354
pubmed: 35979372
Mod Pathol. 2022 Apr;35(4):451-461
pubmed: 34686774
J Clin Exp Hematop. 2022 Jun 28;62(2):60-72
pubmed: 35474035
Nat Rev Dis Primers. 2021 Nov 25;7(1):84
pubmed: 34824298
Hematol Oncol Clin North Am. 2018 Feb;32(1):11-21
pubmed: 29157613
Cancer Immunol Res. 2020 Mar;8(3):321-333
pubmed: 31964625
J Immunol. 2004 Jul 15;173(2):1444-53
pubmed: 15240741
Blood. 2020 Apr 16;135(16):1353-1364
pubmed: 32106302
Nat Rev Immunol. 2006 Apr;6(4):295-307
pubmed: 16557261
Hematol Oncol Clin North Am. 2018 Feb;32(1):23-36
pubmed: 29157617
J Exp Med. 2016 Oct 17;213(11):2281-2291
pubmed: 27670591
Pathol Res Pract. 2019 Oct;215(10):152563
pubmed: 31358479
Pathol Int. 2022 Jan;72(1):43-52
pubmed: 34762752
Cancer Res. 2006 Oct 15;66(20):10145-52
pubmed: 17047079
Gynecol Oncol. 2010 Mar;116(3):556-62
pubmed: 20006900
Mod Rheumatol. 2021 May;31(3):529-533
pubmed: 33274670
Br J Haematol. 2018 Jan;180(2):206-216
pubmed: 29143319